Eagle Asset Management’s Lexicon Pharmaceuticals LXRX Stock Holding History

Eagle Asset Management’s Portfolio LXRX Stock Details LXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-2,832,549	Closed	-$34.5M	–	642
2017 Q3	$34.5M	Sell	2,832,549 -28,516	-1%	-$421K	0.2%	174
2017 Q2	$47.1M	Buy	2,861,065 +8,756	+0.3%	+$136K	0.28%	128
2017 Q1	$40.9M	Sell	2,852,309 -14,307	-0.5%	-$212K	0.26%	126
2016 Q4	$39.6M	Buy	2,866,616 +1,138,662	+66%	+$18.3M	0.26%	123
2016 Q3	$31.2M	Buy	1,727,954 +49,222	+3%	+$792K	0.21%	148
2016 Q2	$24.1M	Buy	1,678,732 +196,759	+13%	+$2.67M	0.17%	181
2016 Q1	$17.7M	Buy	1,481,973 +867,419	+141%	+$9.09M	0.12%	237
2015 Q4	$8.43M	Buy	+614,554	New	+$7.56M	0.06%	355

Other funds holding LXRX

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UIM

USS Investment Management London, United Kingdom $27.8B AUM 39.42% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

CLM

ClearBridge LLC (Maryland) Baltimore, Maryland $329M AUM 9.73% 1-Year Est. Return

Eagle Asset Management's LXRX Position: Q4 2017 in Review

Eagle Asset Management sold out of Lexicon Pharmaceuticals (LXRX) in Q4 2017, closing a stake of 2,832,549 shares — an estimated $34.5M sold.

Eagle Asset Management first reported a position in LXRX in Q4 2015 and held it in 8 quarters. The position peaked at $47.1M in Q2 2017. 133 funds tracked by Wall St. Rank hold LXRX as of Q4 2017.

Eagle Asset Management reported no remaining Lexicon Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
Eagle Asset Management sold 2,832,549 Lexicon Pharmaceuticals shares in Q4 2017, an estimated $34.5M.
Eagle Asset Management first reported a position in Lexicon Pharmaceuticals in Q4 2015 and held it in 8 quarters.
Eagle Asset Management's Lexicon Pharmaceuticals position peaked at $47.1M in Q2 2017.
133 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q4 2017.

Based on Eagle Asset Management's 13F filing for Q4 2017, filed 9 Feb 2018.